✦ LIBER ✦

637 Prediction of the human pharmacokinetics (PK) and pharmacodynamics (PD) of MLN9708, an investigational proteasome inhibitor

✍ Scribed by S.J. Blakemore; A. Bulychev; A. Berger; S. Yu; M. Paton; K. Cardoza; W. Riordan; D. Berg; A. Stathis; L. Yu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

600 Preclinical pharmacokinetics–pharmac

✍ K. Le; A. Chakravarty; R. Walker; E. Izmailova; P. Vincent; S. O'Connell; S. Pra 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 60 KB

280 POSTER Phase I study of the safety,

✍ J. Infante; E.C. Dees; R.B. Cohen; H. Burris; B. O'Neil; P. Murphy; Y. Lee; J. P 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 77 KB

1204 A Phase I study evaluating the phar

✍ R. Kristeleit; D. Sarker; M. Forster; M. Lolkema; D. Olmos; K. Mazina; M.V. Dole 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Safety, Pharmacokinetics (PK), and Pharm

✍ Schranz, J.; Levy, R.; Lumry, W.; Manning, M.; Jacobs, J.; Dychter, S.S.; LaBarr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 38 KB

DRUG-DRUG INTERACTION STUDIES OF CARDIOV

✍ Mendell, Jeanne; Zahir, Halim; Ridout, Graham; Noveck, Robert; Lee, Frank; Chen, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 253 KB

The pharmacokinetics (PK) and pharmacody

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 371 KB